IRLA Stock — IRulya Therapeutics, Inc.

IRulya Therapeutics, Inc. (IRLA)

Updated October 16, 2026.

IRLA is a Stock. Total return is -99.5% over the past 7.4 years, 296.6 points behind SPY at 197.1%.

IRulya Therapeutics, formerly Quince Therapeutics (QNCX), is a clinical-stage biotechnology company focused on LAM-001, an inhaled formulation of rapamycin targeting a key pathway in pulmonary disease. The company took its current name after its merger with privately held Orphai Therapeutics, and its shares began trading under the IRLA ticker on 2026-10-12. This equity security does not currently distribute to shareholders and is suited for investors focused on early-stage biotech development rather than current income.

IRLA performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.5% over the past 7.4 years, 296.6 points behind SPY at 197.1%. Over the past year its total return — price change plus distributions reinvested — is -91.7%. Its deepest 1-year drawdown was 98.2%.

IRLA key facts

Asset type

Stock

Asset class

Equity

Inception date

05/09/2019

Last close

$32.03 (as of 2026-10-16)

Market cap

$32,576,528

Average volume

11597.0

Beta

1.332

Payout ratio

0.0%

EPS

$-214.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IRLA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.2%.

Who may consider IRLA — and who may not

It is a weaker fit for investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IRLA

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions